SCHEMBL24257735

SCHEMBL24257735

Cc1c(-c2ccc3cnccc3c2)cnc(C#N)c1Cl

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX15 P16050 2/20 0.48
CYP11B1 P15538 4/20 0.48
CYP11B2 P19099 4/20 0.48
AKT1 P31749 2/20 0.40
ABL1 P00519 4/20 0.40
TDO2 P48775 2/20 0.39
AR P10275 1/20 0.37
CYP17A1 P05093 1/20 0.36
PRKCI P41743 1/20 0.36
CYP1A2 P05177 1/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2D6 P10635 1/20 0.35
CYP2C9 P11712 1/20 0.35
CYP2C19 P33261 1/20 0.35
CCNT1 O60563 1/20 0.35
CDK9 P50750 1/20 0.35
HASPIN Q8TF76 1/20 0.35
PIK3CD O00329 1/20 0.35
PIK3CA P42336 1/20 0.35
PIK3CB P42338 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30546851 0.86 DHFR (0.43) CYP11B1CYP11B2CYP17A1CYP1A2CYP3A4
SCHEMBL24257623 0.86 DHFR (0.43) CYP11B1CYP11B2CYP17A1CYP1A2CYP3A4
SCHEMBL30453043 0.81 KDM4E (0.38) CYP11B1CYP11B2CYP2C19
SCHEMBL24257513 0.81 KDM4E (0.38) CYP11B1CYP11B2CYP2C19
SCHEMBL30453344 0.80 CYP1A2 (0.39) CYP1A2
SCHEMBL24257719 0.80 CYP1A2 (0.39) CYP1A2
SCHEMBL30546884 0.79 POLB (0.48) CYP11B2ARCYP1A2CYP3A4CYP2C19
SCHEMBL24257739 0.79 POLB (0.48) CYP11B2ARCYP1A2CYP3A4CYP2C19
SCHEMBL24257695 0.78 KDM4E (0.45) CYP11B1CYP11B2CYP17A1CYP1A2CYP3A4
SCHEMBL30453176 0.78 KDM4E (0.45) CYP11B1CYP11B2CYP17A1CYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230295110-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE AKEBIA THERAPEUTICS, INC. (US) 2023-09-21 US disclosed
US-20230295110-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE AKEBIA THERAPEUTICS, INC. (US) 2023-09-21 US disclosed
WO-2022036188-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE AKEBIA THERAPEUTICS, INC. (US) 2022-02-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230295110-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE HIF1AN, EGLN3, PHF20 ALOX15 2214/4885CYP11B1 809/4885CYP11B2 703/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.